Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab
Identificadores
Identificadores
Fecha de publicación
2015Título de revista
ANNALS OF ONCOLOGY
Tipo de contenido
Publicación de congreso